Yunnan Botanee Bio-Technology (300957)

Search documents
贝泰妮(300957) - 简式权益变动报告书-臻丽咨询
2025-05-06 13:18
云南贝泰妮生物科技集团股份有限公司 简式权益变动报告书 上市公司名称:云南贝泰妮生物科技集团股份有限公司 股票上市地点:深圳证券交易所 股票简称:贝泰妮 股票代码:300957 信息披露义务人信息 信息披露义务人:厦门臻丽咨询有限公司 主要经营场所: 厦门市翔安区金海街道新澳路 510 号 705 室之 21 通讯地址:厦门市翔安区金海街道新澳路 510 号 705 室之 21 股份变动性质:股份减少 签署日期:2025 年 5 月 6 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》、《中华人 民共和国证券法》、《上市公司收购管理办法》、《证券期货法律适用意见第19 号——<上市公司收购管理办法>第十三条、第十四条的适用意见》、《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》及其他相关法 律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准,其履行亦不违 反信息披露义务人公司章程或内部规则中的任何条款,或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》、《证券 期货法律适用意见第19号——<上 ...
贝泰妮(300957) - 云南贝泰妮生物科技集团股份有限公司关于股东询价转让结果报告书暨相关股东权益变动的提示性公告
2025-05-06 13:18
证券代码:300957 证券简称:贝泰妮 公告编号:2025-025 云南贝泰妮生物科技集团股份有限公司 关于股东询价转让结果报告书暨相关股东权益变动的提示性公告 股东天津红杉聚业股权投资合伙企业(有限合伙)、厦门臻丽咨询有限公司 保证向本公司提供的信息内容真实、准确、完整,没有虚假记载、误导性陈述或 者重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 1.本次权益变动主体为持有云南贝泰妮生物科技集团股份有限公司(简称"贝 泰妮"或"公司")5%以上股份的股东天津红杉聚业股权投资合伙企业(有限合伙) (以下简称"红杉聚业")、厦门臻丽咨询有限公司(以下简称"臻丽咨询"), 上述股东合称"出让方"。本次权益变动后,红杉聚业拥有权益的股份占公司已发 行股份的比例下降至9.66%(总股本已剔除回购的股份数),其权益变动跨越1%和5% 的整数倍;臻丽咨询拥有权益的股份占公司已发行股份的比例下降至4.53%(总股 本已剔除回购的股份数),持有权益比例降至5%以下。 2. 出让方不属于贝泰妮控股股东、实际控制人、董事、监事及高级管理人员, 本次权益变动不会导致上市公司第一大股 ...
贝泰妮(300957) - 华泰联合证券有限责任公司关于云南贝泰妮生物科技集团股份有限公司股东向特定机构投资者询价转让股份的核查报告
2025-05-06 13:18
向特定机构投资者询价转让股份的核查报告 华泰联合证券有限责任公司 关于云南贝泰妮生物科技集团股份有限公司股东 深圳证券交易所: 华泰联合证券有限责任公司(以下简称"华泰联合证券"或"组织券商") 受委托担任天津红杉聚业股权投资合伙企业(有限合伙)、厦门臻丽咨询有限 公司(以下合称"出让方")以向特定机构投资者询价转让(以下简称"询价 转让")方式减持所持有的云南贝泰妮生物科技集团股份有限公司(以下简称 "公司"或"贝泰妮")首次公开发行前已发行股份的组织券商。 经核查,华泰联合证券就本次询价转让的出让方、受让方是否符合《深圳 证券交易所上市公司自律监管指引第16号——创业板上市公司股东询价和配售 方式转让股份(2025年修订)》(以下简称"《指引第16号》")要求,本次 询价转让的询价、转让过程与结果是否公平、公正,是否符合《指引第16号》 的规定作出如下报告说明。 一、本次询价转让概况 (一)本次询价转让出让方 截至2025年4月25日出让方所持公司首发前股份情况具体如下: | 序号 | 股东名称 | 持股数量(股) | 持股比例 | | --- | --- | --- | --- | | 1 | 天津红杉 ...
贝泰妮(300957):战略调整持续 护肤彩妆双轮助力复苏
Xin Lang Cai Jing· 2025-05-05 10:43
Core Viewpoint - The company reported its 2024 annual report and Q1 2025 results, showing performance slightly below market expectations, with revenue growth but significant declines in net profit and cash flow metrics [1][4]. Financial Performance - 2024 revenue reached 5.736 billion yuan, a year-on-year increase of 3.87%, while net profit attributable to shareholders was 503 million yuan, down 33.53% year-on-year [1]. - Q1 2025 revenue was 949 million yuan, a year-on-year decline of 13.51%, with net profit attributable to shareholders at 28 million yuan, down 83.97% year-on-year [1]. - The company declared a cash dividend of 6.00 yuan per 10 shares (including tax) [1]. Profitability and Cost Structure - The gross margin for 2024 was 73.74%, a decrease of 0.16 percentage points year-on-year, while the net profit margin was 8.63%, down 5.12 percentage points year-on-year [1]. - The sales expense ratio increased to 49.97%, up 2.71 percentage points year-on-year, primarily due to increased brand promotion and online channel costs [1]. - The management expense ratio rose to 8.94%, up 1.46 percentage points year-on-year, attributed to depreciation and personnel costs [1]. Segment Performance - In 2024, skincare revenue was 4.801 billion yuan, down 1.42% year-on-year, while color cosmetics revenue surged to 551 million yuan, a growth of 226.51% year-on-year [2]. - Online channel revenue reached 3.912 billion yuan, up 10.13% year-on-year, with Douyin platform revenue growing by 30.96% to 827 million yuan [2]. Strategic Focus - The company is deepening its "sensitive skin PLUS" strategy, focusing on core products that enhance brand value and sales [3]. - The 2025 strategy will emphasize brand building, membership operations, and collaborative growth, with a focus on scientific communication and emotional content [3]. - The brand matrix includes various sub-brands targeting specific demographics, enhancing market penetration [3][4]. Future Outlook - The company has adjusted its profit forecasts for 2025-2026 and introduced a new forecast for 2027, expecting net profits of 667 million, 769 million, and 899 million yuan respectively [4]. - The price-to-earnings ratio is projected to be 26, 23, and 20 times for 2025, 2026, and 2027 respectively [4].
贝泰妮(300957):战略调整持续,护肤彩妆双轮助力复苏
Shenwan Hongyuan Securities· 2025-05-05 10:11
上 市 公 司 美容护理 2025 年 05 月 05 日 贝泰妮 (300957) ——战略调整持续,护肤彩妆双轮助力复苏 报告原因:有业绩公布需要点评 买入(维持) | 市场数据: | 2025 年 04 月 30 日 | | --- | --- | | 收盘价(元) | 41.41 | | 一年内最高/最低(元) | 74.00/37.46 | | 市净率 | 2.9 | | 股息率%(分红/股价) | 1.45 | | 流通 A 股市值(百万元) | 17,541 | | 上证指数/深证成指 | 3,279.03/9,899.82 | | 注:"股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产(元) | 14.35 | | 资产负债率% | 18.39 | | 总股本/流通 A 股(百万) | 424/424 | | 流通 B 股/H 股(百万) | -/- | 一年内股价与大盘对比走势: 04-30 05-31 06-30 07-31 08-31 09-30 10-31 11-30 12-31 01-31 ...
贝泰妮:2024年报及2025年一季报点评:短期业绩承压,期待经营拐点-20250505
Soochow Securities· 2025-05-05 03:23
2024 年报及 2025 年一季报点评:短期业绩 承压,期待经营拐点 买入(维持) | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 5,522 | 5,736 | 6,214 | 6,718 | 7,284 | | 同比(%) | 10.14 | 3.87 | 8.33 | 8.11 | 8.43 | | 归母净利润(百万元) | 756.80 | 503.05 | 660.45 | 808.77 | 935.70 | | 同比(%) | (28.02) | (33.53) | 31.29 | 22.46 | 15.69 | | EPS-最新摊薄(元/股) | 1.79 | 1.19 | 1.56 | 1.91 | 2.21 | | P/E(现价&最新摊薄) | 23.18 | 34.87 | 26.56 | 21.69 | 18.75 | [Table_Tag] [Table_Summary] 投资要点 2025 年 05 ...
国货美妆十强榜单揭晓:百亿时代,谁在引领变革?
FBeauty未来迹· 2025-04-30 09:27
2 0 2 4年在国货美妆发展史上是值得记录一年: 一方面,国内诞生首个突破百亿美妆企业,珀莱雅以1 0 7 . 7 8亿元营收首次跻身"百亿俱乐部", 成 为 行 业 里 程 碑 事 件 ; 同 时 , 十 强 门 槛 抬 高 至 近 3 0 亿 元 , 前 十 总 营 收 规 模 扩 大 至 5 4 3 . 7 7 亿 元。 另一方面,前十座次发生较大变化,毛戈平首次闯入榜单,上海家化、华熙生物等企业持续步 入变革期深水区,迎来业绩"震荡"。 在"突飞猛进"与震荡调整并存的阶段,头部国货企业的发展预示着行业怎样的未来? 综 合 2 0 2 1 年 至 2 0 2 4 年 国 货 美 妆 上 市 企 业 十 强 榜 单 情 况 来 看 , 可 以 发 现 , 名 次 发 生 了 较 大 变 化。每一年的前三名都不相同,并且持续有"突围者"闯入榜单,例如2 0 2 4年的毛戈平。 | | | | 2021年至2024年国货美妆上市企业十强榜单 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | -- ...
贝泰妮(300957):2024年年报及2025年一季报点评:短期利润承压,积极进行业务变革优化
EBSCN· 2025-04-29 14:42
Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company experienced a 3.9% year-on-year increase in revenue for 2024, reaching 5.74 billion yuan, while the net profit attributable to shareholders decreased by 33.5% to 500 million yuan [5][11] - The first quarter of 2025 saw a significant decline in performance, with revenue dropping by 14% year-on-year to 950 million yuan and net profit down 84% to 28.34 million yuan [6][11] - The company is undergoing business transformation and optimization, focusing on brand operation and member management to strengthen its market position [11] Financial Performance Summary - In 2024, the company reported a revenue of 5.74 billion yuan, with a net profit of 500 million yuan, and a basic EPS of 1.20 yuan [5][11] - The gross margin for 2024 was 73.7%, slightly down from the previous year, but has shown signs of recovery since Q4 2024 [8][11] - The company’s operating cash flow for 2024 was 690 million yuan, reflecting a 13.8% increase year-on-year [10] Revenue Breakdown - In 2024, online channels contributed 68% of total revenue, with a year-on-year growth of 10.1%, while offline channels accounted for 22% with a decline of 10.7% [7][11] - The skincare segment remains the largest contributor to revenue at 84%, although it saw a slight decline of 1.4% year-on-year [7][11] Cost and Expense Analysis - The company’s expense ratio increased by 4.3 percentage points to 64% in 2024, driven by higher sales and management expenses [8][11] - The sales expense ratio rose to 50%, primarily due to increased marketing and promotional activities [9][11] Future Earnings Forecast - The report projects net profits of 690 million yuan, 830 million yuan, and 1 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS estimates of 1.62 yuan, 1.97 yuan, and 2.36 yuan [11][12]
贝泰妮(300957) - 国信证券股份有限公司关于云南贝泰妮生物科技集团股份有限公司首次公开发行股票并在创业板上市的保荐总结报告书
2025-04-29 09:38
国信证券股份有限公司 关于云南贝泰妮生物科技集团股份有限公司 首次公开发行股票并在创业板上市的保荐总结报告书 国信证券股份有限公司(以下简称"国信证券"或"保荐机构")作为云南 贝泰妮生物科技集团股份有限公司(以下简称"贝泰妮"或"公司")首次公开 发行股票并在创业板上市的保荐机构,持续督导期限截至 2024 年 12 月 31 日。 目前,持续督导期限已届满。国信证券根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 13 号——保荐业务》等有关法规和规范性文件的要求,对贝泰妮履行持续 督导义务并出具本持续督导保荐总结报告书。 | 保荐人名称 | 国信证券股份有限公司 | | --- | --- | | 保荐人编号 | Z27074000 | 一、保荐机构及保荐代表人承诺 (一)保荐总结报告书和证明文件及相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏,保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 (二)保荐机构及保荐代表人自愿接受中国证券监督管理委员会(以下简称 "中国证监会")对保荐总结报告书相关事项进行的任何质询和调 ...
贝泰妮(300957):2024年年报、2025年一季报点评:营收稳健增长,利润略有承压
Minsheng Securities· 2025-04-29 07:24
Investment Rating - The report maintains a "Recommended" rating for the company, with a target price based on projected earnings growth and valuation metrics [4][5]. Core Insights - The company reported a revenue of 5.736 billion yuan for 2024, reflecting a year-on-year growth of 3.87%. However, the net profit attributable to shareholders decreased by 33.53% to 503 million yuan [2][5]. - The main revenue source is the brand "Winona," which saw a revenue decline of 5.45% to 4.909 billion yuan, while "Winona Baby" and "Aikeman" experienced significant growth of 34.03% and 65.59%, respectively [2][4]. - The gross margin for 2024 was 73.74%, with a slight decrease of 0.16 percentage points year-on-year. The net profit margin decreased by 4.93 percentage points to 8.77% [3][4]. Financial Performance Summary - Revenue projections for 2025, 2026, and 2027 are 6.285 billion yuan, 7.153 billion yuan, and 8.146 billion yuan, respectively, with growth rates of 9.6%, 13.8%, and 13.9% [5][7]. - The net profit attributable to shareholders is expected to recover to 700 million yuan in 2025, with a growth rate of 39.2%, followed by 856 million yuan in 2026 and 1.059 billion yuan in 2027 [5][7]. - The report indicates an increase in operating expenses, with sales, management, and R&D expense ratios rising significantly in recent quarters [3][4]. Brand Strategy and Market Position - The company is expanding its market presence with a multi-brand strategy, focusing on the main brand "Winona" and introducing new products in the sensitive skin segment [4]. - The launch of the "Winona 2.0" strategy aims to enhance brand positioning and product offerings, which is expected to drive long-term growth [4][5].